Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
Renal function and venous thromboembolic diseases
J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agent...
Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research
